CLINICAL_TRIALS
trial_result
· 2018-10-17
Clinical Trial Update: A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging [Phase 2]
Summary
Phase 2 trial evaluating 3-month dosing with GW856553 and assessing FDG-PET/CT imaging in atherosclerosis; study completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Atherosclerosis | Phase 2 | Status: COMPLETED | Results posted: 2018-10-17